Annual report pursuant to Section 13 and 15(d)

Nature of Business and Liquidity (Details)

v3.20.1
Nature of Business and Liquidity (Details)
12 Months Ended
Dec. 31, 2019
drug
Dec. 31, 2019
drug
approach
Dec. 31, 2019
project
drug
Dec. 31, 2019
drug
technology
Dec. 31, 2019
drug
Dec. 31, 2019
candidate
drug
Feb. 28, 2019
Subsequent Event [Line Items]              
Number of drug technologies | technology       3      
Number of drug candidates         6 6  
Number of different approaches to treating cancer | approach   3          
Number of other drug development projects | project     5        
Number of drugs in clinical trials | drug 2 2 2 2 2 2  
Licensing Agreements              
Subsequent Event [Line Items]              
Market exclusivity period 7 years            
ALI              
Subsequent Event [Line Items]              
Ownership percentage in equity method investment             10.00%
EU              
Subsequent Event [Line Items]              
Market exclusivity extension period 10 years            
Food and Drug Administration              
Subsequent Event [Line Items]              
Market exclusivity extension period 5 years